-
Mashup Score: 0
The phase 3 KEYNOTE-B21 study missed its primary end point, as pembrolizumab plus chemotherapy did not improve disease-free survival in newly diagnosed, high-risk endometrial cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
A phase 3 study evaluating uproleselan in relapsed/refractory acute myeloid leukemia missed its primary end point of overall survival.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0AGAVE-201 Data on Refractory cGvHD - 13 hour(s) ago
In this expert analysis of the AGAVE-201 trial data, the efficacy of a monoclonal antibody in treating graft versus host disease is discussed, with the lowest dose of 0.3 mg/kg administered every 2 weeks demonstrating the highest response rates, exceeding 75%.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Oncolytic Viruses: A Promising New Option in Cancer Treatment - 15 hour(s) ago
As part of its Speaking Out video series, Targeted Oncology spoke with Howard D. Edington, MD, about the benefits of using oncolytic viruses in cancer treatment.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Exploring the Frailty Factor in Stem Cell Transplant Hospitalization - 17 hour(s) ago
In an interview with Targeted Oncology, Kayla Giannetti, MSN, APRN-CNP, discussed the background of the study, along with its findings and implications for community oncologists.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC - 19 hour(s) ago
In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5World Ovarian Cancer Day: Education and Advances in Treatment - 22 hour(s) ago
For World Ovarian Cancer Day, Eirwen M. Miller, MD, discussed the current state of ovarian cancer treatment, new developments in the space, and unmet needs.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Understanding the Deep Response to Pacritinib in Myelofibrosis - 23 hour(s) ago
During a Case-Based Roundtable® event, John Mascarenhas, MD, discussed the deep response with pacritinib and its adverse event profile for patients with myelofibrosis in the second article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Treatment Approaches for Myeloproliferative Neoplasms - 1 day(s) ago
This segment discusses the current classification of myeloproliferative neoplasms (MPNs) and the pathogenesis of these disorders, particularly the role of the JAK-STAT signaling pathway. It also presents a treatment algorithm for higher-risk myelofibrosis, with a focus on the use of JAK inhibitors such as ruxolitinib, fedratinib, pacritinib, and momelotinib.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
Pembrolizumab + adjuvant chemotherapy with/without radiotherapy did not improve disease-free survival in patients with newly diagnosed, high-risk endometrial cancer, missing the primary end point of the phase 3 KEYNOTE-B21 study. #GYNCSM | @Merck https://t.co/whwaKhESYe